ストックスクリーナーアプリを入手
8.75
1.74%
0.15
アフターアワーズ：
8.72
-0.03
-0.34%
前日終値:
$8.60
開ける：
$8.53
24時間の取引高:
3.02M
Relative Volume:
1.40
時価総額：
$508.91M
収益：
$161.10M
当期純損益:
$-308.60M
株価収益率:
-1.8737
EPS:
-4.67
ネットキャッシュフロー:
$-259.90M
1週間 パフォーマンス:
+18.24%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-66.03%
1年 パフォーマンス:
-74.80%
1日の値動き範囲:
$8.21
$8.88
1週間の範囲:
$7.2288
$8.88
52週間の値動き範囲:
$5.935
$37.38
Arvinas Inc Stock (ARVN) Company Profile
ARVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
8.75 | 508.91M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2025-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-03-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2024-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-01 | 開始されました | Goldman | Buy |
| 2023-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-11-20 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-10-23 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-01-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 開始されました | Barclays | Overweight |
| 2022-06-21 | 開始されました | Jefferies | Hold |
| 2022-05-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-04-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2022-01-19 | 開始されました | Goldman | Buy |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-09 | 開始されました | BofA Securities | Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-21 | 開始されました | Truist | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-12-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-06-01 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Perform |
| 2019-12-19 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-25 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-25 | 開始されました | Wedbush | Outperform |
| 2019-09-12 | 開始されました | BMO Capital Markets | Outperform |
| 2019-08-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-22 | 開始されました | Citigroup | Buy |
| 2018-10-22 | 開始されました | Goldman | Neutral |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Arvinas Inc (ARVN) 最新ニュース
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting | ARVN Stock News - GuruFocus
Arvinas to Present Preclinical Data for PROTAC BCL6 - GlobeNewswire
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American - Bluefield Daily Telegraph
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting - TradingView
Breakthrough Cancer Treatment ARV-393 Demonstrates Powerful Results Against Lymphoma in Latest Research - Stock Titan
Federated Hermes Inc. Cuts Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Affinity Asset Advisors LLC Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Decreases By 28.2% - MarketBeat
Franklin Resources Inc. Has $489,000 Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Stock Position Increased by New Leaf Venture Partners L.L.C. - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Kennedy Capital Management LLC - MarketBeat
Arvinas (NASDAQ:ARVN) shareholders are up 16% this past week, but still in the red over the last three years - simplywall.st
(ARVN) Trading Report - news.stocktradersdaily.com
Arvinas (NASDAQ:ARVN) Price Target Lowered to $21.00 at Truist Financial - MarketBeat
JPMorgan Chase & Co. Sells 472,225 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Vanguard Group Inc. Has $135.39 Million Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
HC Wainwright Reiterates Buy Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Finepoint Capital LP Acquires 139,400 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Norges Bank Purchases New Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
American Century Companies Inc. Sells 58,788 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (ARVN) Reports Positive Phase 3 Trial Results in Breast Cancer Treatment - GuruFocus
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arvinas stock target cut to $21 from $65 at Truist Securities - Investing.com Canada
Arvinas stock target cut to $21 from $65 at Truist Securities By Investing.com - Investing.com South Africa
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple - Insider Monkey
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN) - Yahoo Finance
Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating - marketscreener.com
10 Stocks Under $10 that Will Triple - Insider Monkey
H.C. Wainwright maintains $81 target on Arvinas stock post-data By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $81 target on Arvinas stock post-data - Investing.com
Edmond DE Rothschild Holding S.A. Acquires Shares of 80,000 Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas stock plunges to 52-week low at $6.46 amid market rout - Investing.com Canada
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study - AOL.com
Arvinas stock plunges to 52-week low at $6.46 amid market rout By Investing.com - Investing.com South Africa
Arvinas Holding Company Unveils Promising ARV-102 Trial Results - TipRanks
Arvinas : MoneyGram and Mastercard collaborate to advance digital money movement - MarketScreener
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s - Yahoo
Arvinas Presents First-in-Human Data For ARV-102 In Neurodegenerative Diseases, Stock Down - Nasdaq
Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2 - MarketScreener
Arvinas Inc (ARVN) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):